Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 194

1.

Impacts of human papillomavirus vaccination for different populations: A modeling study.

Baussano I, Lazzarato F, Ronco G, Franceschi S.

Int J Cancer. 2018 Mar 30. doi: 10.1002/ijc.31409. [Epub ahead of print]

PMID:
29603224
2.

Assessment of viral methylation levels for high risk HPV types by newly designed consensus primers PCR and pyrosequencing.

Gillio-Tos A, Fiano V, Grasso C, Trevisan M, Gori S, Mongia A, De Marco L, Ronco G; and the New Technologies for Cervical Cancer Screening (NTCC) Working Group.

PLoS One. 2018 Mar 26;13(3):e0194619. doi: 10.1371/journal.pone.0194619. eCollection 2018.

3.

Invitation strategies and coverage in the population-based cancer screening programmes in the European Union.

Vale DB, Anttila A, Ponti A, Senore C, Sankaranaryanan R, Ronco G, Segnan N, Tomatis M, Žakelj MP, Elfström KM, Lönnberg S, Dillner J, Basu P.

Eur J Cancer Prev. 2018 Mar 21. doi: 10.1097/CEJ.0000000000000426. [Epub ahead of print]

PMID:
29570103
4.

Author's reply to: Cancer screening policy in Hungary.

Basu P, Ponti A, Anttila A, Ronco G, Senore C, Vale DB, Segnan N, Tomatis M, Soerjomataram I, Primic Žakelj M, Dillner J, Elfström KM, Lönnberg S, Sankaranarayanan R.

Int J Cancer. 2018 Mar 10. doi: 10.1002/ijc.31371. [Epub ahead of print] No abstract available.

PMID:
29524204
5.

Human papilloma virus genotyping for the cross-sectional and longitudinal probability of developing cervical intraepithelial neoplasia grade 2 or more.

Del Mistro A, Adcock R, Carozzi F, Gillio-Tos A, De Marco L, Girlando S, Rizzolo R, Frayle H, Trevisan M, Sani C, Burroni E, Giorgi Rossi P, Cuzick J, Ronco G; New Technologies for Cervical CancerWorking Group.

Int J Cancer. 2018 Feb 17. doi: 10.1002/ijc.31326. [Epub ahead of print]

PMID:
29453769
6.

Small non-coding RNA profiling in human biofluids and surrogate tissues from healthy individuals: description of the diverse and most represented species.

Ferrero G, Cordero F, Tarallo S, Arigoni M, Riccardo F, Gallo G, Ronco G, Allasia M, Kulkarni N, Matullo G, Vineis P, Calogero RA, Pardini B, Naccarati A.

Oncotarget. 2017 Dec 14;9(3):3097-3111. doi: 10.18632/oncotarget.23203. eCollection 2018 Jan 9.

7.

Eurogin roadmap 2017: Triage strategies for the management of HPV-positive women in cervical screening programs.

Cuschieri K, Ronco G, Lorincz A, Smith L, Ogilvie G, Mirabello L, Carozzi F, Cubie H, Wentzensen N, Snijders P, Arbyn M, Monsonego J, Franceschi S.

Int J Cancer. 2018 Jan 17. doi: 10.1002/ijc.31261. [Epub ahead of print] Review.

PMID:
29341110
8.

Causal system modelling of cervical cancer screening.

Ronco G, Baussano I.

Lancet Public Health. 2017 Feb;2(2):e61-e62. doi: 10.1016/S2468-2667(17)30013-0. Epub 2017 Feb 7. No abstract available.

9.

Cervical Cancer Screening: The Transformational Role of Routine Human Papillomavirus Testing.

Ronco G, Franceschi S.

Ann Intern Med. 2018 Jan 2;168(1):75-76. doi: 10.7326/M17-2872. Epub 2017 Nov 28. No abstract available.

PMID:
29181508
10.

Status of implementation and organization of cancer screening in The European Union Member States-Summary results from the second European screening report.

Basu P, Ponti A, Anttila A, Ronco G, Senore C, Vale DB, Segnan N, Tomatis M, Soerjomataram I, Primic Žakelj M, Dillner J, Elfström KM, Lönnberg S, Sankaranarayanan R.

Int J Cancer. 2018 Jan 1;142(1):44-56. doi: 10.1002/ijc.31043. Epub 2017 Oct 10. Erratum in: Int J Cancer. 2018 Jul 1;143(1):E1.

PMID:
28940326
11.

Role of HPV DNA testing in modern gynaecological practice.

Ronco G, Giorgi Rossi P.

Best Pract Res Clin Obstet Gynaecol. 2018 Feb;47:107-118. doi: 10.1016/j.bpobgyn.2017.08.002. Epub 2017 Aug 12. Review.

PMID:
28918099
12.

Different Challenges in Eliminating HPV16 Compared to Other Types: A Modeling Study.

Baussano I, Lazzarato F, Ronco G, Lehtinen M, Dillner J, Franceschi S.

J Infect Dis. 2017 Aug 1;216(3):336-344. doi: 10.1093/infdis/jix299.

13.

Inequalities in cervical cancer screening utilisation and results: A comparison between Italian natives and immigrants from disadvantaged countries.

Gallo F, Caprioglio A, Castagno R, Ronco G, Segnan N, Giordano L.

Health Policy. 2017 Oct;121(10):1072-1078. doi: 10.1016/j.healthpol.2017.08.005. Epub 2017 Aug 10.

PMID:
28843514
14.

[Implementation of DNA-HPV primary screening in Italian cervical cancer screening programmes. Results of the MIDDIR Project].

Di Stefano F, Giorgi Rossi P, Carozzi F, Ronco G, Cacciani L, Vecchi S, Naldoni C, Segnan N; Gruppo di lavoro MIDDIR – HPV test in primary screening.

Epidemiol Prev. 2017 Mar-Apr;41(2):116-124. doi: 10.19191/EP17.2.P116.031. Italian.

PMID:
28627153
15.

Determinants of Viral Oncogene E6-E7 mRNA Overexpression in a Population-Based Large Sample of Women Infected by High-Risk Human Papillomavirus Types.

Giorgi Rossi P, Bisanzi S, Allia E, Mongia A, Carozzi F, Gillio-Tos A, De Marco L, Ronco G, Gustinucci D, Del Mistro A, Frayle H, Iossa A, Fantacci G, Pompeo G, Cesarini E, Bulletti S, Passamonti B, Rizzi M, Penon MG, Barca A, Benevolo M.

J Clin Microbiol. 2017 Apr;55(4):1056-1065. doi: 10.1128/JCM.01794-16. Epub 2017 Jan 18.

16.

Interobserver reproducibility of cytologic p16INK4a /Ki-67 dual immunostaining in human papillomavirus-positive women.

Benevolo M, Allia E, Gustinucci D, Rollo F, Bulletti S, Cesarini E, Passamonti B, Giovagnoli MR, Carico E, Carozzi FM, Mongia A, Fantacci G, Confortini M, Rubino T, Fodero C, Prandi S, Marchi N, Farruggio A, Coccia A, Macrì L, Ghiringhello B, Ronco G, Bragantini E, Polla E, Maccallini V, Negri G, Giorgi Rossi P; New Technologies for Cervical Cancer Screening 2 (NTCC2) Working Group.

Cancer Cytopathol. 2017 Mar;125(3):212-220. doi: 10.1002/cncy.21800. Epub 2016 Dec 7.

17.

Cervical cancer screening in women vaccinated against human papillomavirus infection: Recommendations from a consensus conference.

Giorgi Rossi P, Carozzi F, Federici A, Ronco G, Zappa M, Franceschi S; Italian Screening in HPV vaccinated girls Consensus Conference group.

Prev Med. 2017 May;98:21-30. doi: 10.1016/j.ypmed.2016.11.020. Epub 2016 Nov 25.

18.

Impact of variations in triage cytology interpretation on human papillomavirus-based cervical screening and implications for screening algorithms.

Ronco G, Zappa M, Franceschi S, Tunesi S, Caprioglio A, Confortini M, Del Mistro A, Carozzi F, Segnan N, Zorzi M, Giorgi-Rossi P; Italian HPV Survey Working Group.

Eur J Cancer. 2016 Nov;68:148-155. doi: 10.1016/j.ejca.2016.09.008. Epub 2016 Oct 15.

19.

PERS&O (PERsistent Sitagliptin treatment & Outcomes): observational retrospective study on cardiovascular risk evolution in patients with type 2 diabetes on persistent sitagliptin treatment.

Buonaiuto G, De Mori V, Braus A, Balini A, Berzi D, Carpinteri R, Forloni F, Meregalli G, Ronco GL, Bossi AC.

BMJ Open Diabetes Res Care. 2016 Jul 14;4(1):e000216. doi: 10.1136/bmjdrc-2016-000216. eCollection 2016.

20.

Sugammadex: The Right Option for the Efficiency of the Operating Room? A Methodology for Cost / Benefit Analysis in Comparison to the Routine Choice for Reversal.

Ronco GL.

Value Health. 2015 Nov;18(7):A732. doi: 10.1016/j.jval.2015.09.2800. Epub 2015 Oct 20. No abstract available.

Supplemental Content

Support Center